Dry eye a constantly changing landscape
September 1st 2005Washington, DC-Dry eye disease affects millions of people worldwide and with that has come a recent greater awareness among patients that it is indeed a problem. As the recognition of the magnitude of dry eye is changing, so too has knowledge of its pathogenesis, the technology facilitating diagnosis, and the drugs that are becoming available to treat it. General ophthalmologists will be increasingly challenged to learn more about the disease and the best ways to treat individual patients, according to Michael Lemp, MD.
Genetic testing may be key to helping rare eye diseases
September 1st 2005Orlando—When a child receives the diagnosis of Leber's congenital amaurosis (LCA) or another genetically based disease, too often parents hear from the ophthalmologist that nothing can be done. Whether the doctor intends to deliver such a negative message or conveys it inadvertently by using cold, clinical terminology, it is the wrong message, according to Edwin M. Stone, MD, PhD.
High-frequency UBM helpful tool in strabismus reoperation
September 1st 2005Orlando—The high-frequency ultrasound biomicroscope (UBM) can reliably estimate the distance of horizontal muscle insertion from the limbus in eyes that had previous strabismus surgery on the same muscle, according to Shuan H. Dai, MB, BS, FRANZCO, a pediatric ophthalmologist.
Pegaptanib earns praise as 'product of the year'
September 1st 2005New York—Pegaptanib sodium injection (Macugen) has won recognition as a major scientific breakthrough from an organization accustomed to novel pharmaceutical products. The drug, the first FDA-approved treatment for wet age-related macular degeneration (AMD), was named Innovative Pharmaceutical Product of the Year at the 2005 Pharmaceutical Achievement Awards.
Are we no longer a nation built upon risk?
September 1st 2005At a recent meeting of department directors, the president of my university, William Brody, MD, PhD, made an offhand comment that resonated with me. He noted that "the citizens of the United States, a nation built upon risk, seem no longer willing to accept any risk."
Surgical intervention beneficial to adult strabismus
September 1st 2005Orlando—A questionnaire administered to adults who underwent surgery for strabismus showed that most patients believed any disabilities related to this condition improved after the procedure, said George R. Beauchamp, MD, FACS, professor of clinical ophthalmology, University of Texas Southwestern Medical School, Dallas.
Visual complaints seen with neurodegenerative diseases
August 15th 2005St. Louis—Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy, are characterized by visual complaints, which must be assessed carefully to establish the correct diagnosis.
Intravitreal Sod2 injections able to rescue RGCs in mice
August 15th 2005Fort Lauderdale, FL—A potential new strategy has been proposed to treat optic neuritis and multiple sclerosis, namely, delivery of the superoxide dismutase (Sod) 2 gene. Intravitreal Sod2 injections in mice suppressed myelin fiber injury and rescued the retinal ganglion cells (RGCs) for up to 1 year after the inoculation, according to John Guy, MD.
Knowing services aspect key to marketing direction
August 15th 2005Understanding the fundamentals of services marketing is extremely useful for the optimal marketing of a medical practice. Basic knowledge in this area is also helpful when studying the marketing approach of your competitors. Additionally, you may consider these concepts when analyzing ads for which you are the targeted customer.
Liquefaction device is good alternative for cataract surgery
August 15th 2005Miami—Cataract surgeons performing standard ultrasound phacoemulsification will find the AquaLase liquefaction device (Alcon Laboratories) is an easy technique to transition to and is one that offers multiple advantages for enhancing the safety of lens removal, said Sonia H. Yoo, MD.
Sharp optic edge of IOL appears protective against PCO
August 15th 2005Frankfurt, Germany—The design of the optic edge seems to be one of the most important factors in the development of posterior capsule opacification (PCO). IOLs with a sharp edge have less PCO regardless of the lens material, according to Thomas Kohnen, MD.
Novel causative gene identified for adult-onset POAG
August 15th 2005Fort Lauderdale, FL—WDR36 is a novel causative gene for adult-onset primary open-angle glaucoma (POAG) that is located at the GLC1G locus. Sharareh Monemi, MD, PhD, and Mansoor Sarfarazi, PhD, explained that this discovery should help in the diagnosis and treatment of glaucoma.